» Articles » PMID: 37471463

Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment

Abstract

Purpose: Despite limited genetic and histologic heterogeneity, Ewing sarcoma (EwS) tumor cells are transcriptionally heterogeneous and display varying degrees of mesenchymal lineage specification in vitro. In this study, we investigated if and how transcriptional heterogeneity of EwS cells contributes to heterogeneity of tumor phenotypes in vivo.

Experimental Design: Single-cell proteogenomic-sequencing of EwS cell lines was performed and integrated with patient tumor transcriptomic data. Cell subpopulations were isolated by FACS for assessment of gene expression and phenotype. Digital spatial profiling and human whole transcriptome analysis interrogated transcriptomic heterogeneity in EwS xenografts. Tumor cell subpopulations and matrix protein deposition were evaluated in xenografts and patient tumors using multiplex immunofluorescence staining.

Results: We identified CD73 as a biomarker of highly mesenchymal EwS cell subpopulations in tumor models and patient biopsies. CD73+ tumor cells displayed distinct transcriptional and phenotypic properties, including selective upregulation of genes that are repressed by EWS::FLI1, and increased migratory potential. CD73+ cells were distinguished in vitro and in vivo by increased expression of matrisomal genes and abundant deposition of extracellular matrix (ECM) proteins. In epithelial-derived malignancies, ECM is largely deposited by cancer-associated fibroblasts (CAF), and we thus labeled CD73+ EwS cells, CAF-like tumor cells. Marked heterogeneity of CD73+ EwS cell frequency and distribution was detected in tumors in situ, and CAF-like tumor cells and associated ECM were observed in peri-necrotic regions and invasive foci.

Conclusions: EwS tumor cells can adopt CAF-like properties, and these distinct cell subpopulations contribute to tumor heterogeneity by remodeling the tumor microenvironment. See related commentary by Kuo and Amatruda, p. 5002.

Citing Articles

Tumor-associated stroma shapes the spatial tumor immune microenvironment of primary Ewing sarcomas.

Kuo C, Giannikou K, Wang N, Warren M, Goodspeed A, Shillingford N bioRxiv. 2025; .

PMID: 39975230 PMC: 11838416. DOI: 10.1101/2025.01.31.635996.


Caveolin-1 regulates context-dependent signaling and survival in Ewing sarcoma.

Segal D, Wang X, Mazloom-Farisbaf H, Rajendran D, Butler E, Chen B bioRxiv. 2024; .

PMID: 39713413 PMC: 11661136. DOI: 10.1101/2024.09.23.614468.


EWS-FLI1 and Activator Protein-1 (AP-1) Reciprocally Regulate Extracellular-Matrix Proteins in Ewing sarcoma Cells.

Croushore E, Stipp C, Gordon D Int J Mol Sci. 2024; 25(16).

PMID: 39201282 PMC: 11354993. DOI: 10.3390/ijms25168595.


Correlation analysis of disulfidptosis-related gene signatures with clinical prognosis and immunotherapy response in sarcoma.

Xu J, Guo K, Sheng X, Huang Y, Wang X, Dong J Sci Rep. 2024; 14(1):7158.

PMID: 38531930 PMC: 10966107. DOI: 10.1038/s41598-024-57594-x.


TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.

Schober S, Thiede M, Gassmann H, von Ofen A, Knoch P, Eck J Front Immunol. 2024; 15:1330868.

PMID: 38318175 PMC: 10839048. DOI: 10.3389/fimmu.2024.1330868.


References
1.
Lu D, Ellegast J, Ross K, Malone C, Lin S, Mabe N . The ETS transcription factor ETV6 constrains the transcriptional activity of EWS-FLI to promote Ewing sarcoma. Nat Cell Biol. 2023; 25(2):285-297. PMC: 9928584. DOI: 10.1038/s41556-022-01059-8. View

2.
Jin M, Jin W . The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020; 5(1):166. PMC: 7447642. DOI: 10.1038/s41392-020-00280-x. View

3.
Greaves M . Evolutionary determinants of cancer. Cancer Discov. 2015; 5(8):806-20. PMC: 4539576. DOI: 10.1158/2159-8290.CD-15-0439. View

4.
McGranahan N, Swanton C . Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017; 168(4):613-628. DOI: 10.1016/j.cell.2017.01.018. View

5.
Zollner S, Amatruda J, Bauer S, Collaud S, de Alava E, Dubois S . Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. J Clin Med. 2021; 10(8). PMC: 8071040. DOI: 10.3390/jcm10081685. View